These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations. Levin MD; Kater AP; Mattsson M; Kersting S; Ranti J; Thi Tuyet Tran H; Nasserinejad K; Niemann CU BMJ Open; 2020 Oct; 10(10):e039168. PubMed ID: 33060089 [TBL] [Abstract][Full Text] [Related]
28. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692 [TBL] [Abstract][Full Text] [Related]
29. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803 [TBL] [Abstract][Full Text] [Related]
30. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671 [TBL] [Abstract][Full Text] [Related]
31. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. Thompson MC; Mato AR Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986 [TBL] [Abstract][Full Text] [Related]
32. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251 [TBL] [Abstract][Full Text] [Related]
33. Venetoclax Yields Strong Responses in CLL. Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089 [TBL] [Abstract][Full Text] [Related]
34. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474 [TBL] [Abstract][Full Text] [Related]
35. Venetoclax plus rituximab for chronic lymphocytic leukaemia. Stirrups R Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585 [No Abstract] [Full Text] [Related]
36. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Kater AP; Slinger E; Cretenet G; Martens AW; Balasubramanian S; Leverson JD; Eldering E Blood Adv; 2021 Dec; 5(23):5410-5414. PubMed ID: 34555843 [TBL] [Abstract][Full Text] [Related]
37. Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis. Sheng Z; Song S; Yu M; Zhu H; Gao A; Gao W; Ran X; Huo D Leuk Lymphoma; 2020 Dec; 61(14):3432-3439. PubMed ID: 32862749 [TBL] [Abstract][Full Text] [Related]
38. Venetoclax for the treatment of chronic lymphocytic leukemia. Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395 [TBL] [Abstract][Full Text] [Related]
39. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613 [TBL] [Abstract][Full Text] [Related]
40. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? Suzumiya J; Takizawa J Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]